BACKGROUND: Elevated urinary albumin excretion (UAE) is associated with the risk of cardiovascular disease (CVD) and all-cause mortality. We tested the hypothesis that elevated UAE improves cardiovascular risk stratification in an elderly cohort aged 68-102 years. METHODS: We evaluated UAE in 3112 participants of the Cardiovascular Health Study who attended the 1996-1997 examination and had median follow up of 5.4 years. Elevated UAE was defined as urinary albumin to creatinine ratio > or =30 microg/mg. Microalbuminuria and macroalbuminuria were defined as urinary albumin to creatinine ratio 30-300 microg/mg and >300 microg/mg, respectively. Outcomes included CVD (myocardial infarction, stroke, cardiovascular death) and all-cause mortality. Cox proportional hazards models were used to assess the risk of outcomes associated with elevated UAE. RESULTS: The prevalence of elevated UAE was 14.3%, 17.1% and 26.9% in those aged 68-74, 75-84 and 85-102 years, respectively. CVD incidence and all-cause mortality were doubled (7.2% and 8.1% per year) in those with microalbuminuria and tripled (11.1% and 12.3% per year) in those with macroalbuminuria compared to those with normal UAE (3.3% and 3.8% per year). The increased CVD and mortality risks were observed in all age groups after adjustment for conventional risk factors. The adjusted population attributable risk percent of CVD and all-cause mortality for elevated UAE was 11% and 12%, respectively. When participants were cross-classified by UAE and Framingham Risk Score categories, the 5-year cumulative incidence of coronary heart disease among participants with elevated UAE and a 5-year predicted risk of 5-10% was 20%, substantially higher than 6.3% in those with UAE <30m microg/mg. CONCLUSION: Elevated UAE was associated with an increased risk of CVD and all-cause mortality in all age groups from 68 to 102 years. Combining elevated UAE with the Framingham risk scores may improve risk stratification for CVD in the elderly.
BACKGROUND: Elevated urinary albumin excretion (UAE) is associated with the risk of cardiovascular disease (CVD) and all-cause mortality. We tested the hypothesis that elevated UAE improves cardiovascular risk stratification in an elderly cohort aged 68-102 years. METHODS: We evaluated UAE in 3112 participants of the Cardiovascular Health Study who attended the 1996-1997 examination and had median follow up of 5.4 years. Elevated UAE was defined as urinary albumin to creatinine ratio > or =30 microg/mg. Microalbuminuria and macroalbuminuria were defined as urinary albumin to creatinine ratio 30-300 microg/mg and >300 microg/mg, respectively. Outcomes included CVD (myocardial infarction, stroke, cardiovascular death) and all-cause mortality. Cox proportional hazards models were used to assess the risk of outcomes associated with elevated UAE. RESULTS: The prevalence of elevated UAE was 14.3%, 17.1% and 26.9% in those aged 68-74, 75-84 and 85-102 years, respectively. CVD incidence and all-cause mortality were doubled (7.2% and 8.1% per year) in those with microalbuminuria and tripled (11.1% and 12.3% per year) in those with macroalbuminuria compared to those with normal UAE (3.3% and 3.8% per year). The increased CVD and mortality risks were observed in all age groups after adjustment for conventional risk factors. The adjusted population attributable risk percent of CVD and all-cause mortality for elevated UAE was 11% and 12%, respectively. When participants were cross-classified by UAE and Framingham Risk Score categories, the 5-year cumulative incidence of coronary heart disease among participants with elevated UAE and a 5-year predicted risk of 5-10% was 20%, substantially higher than 6.3% in those with UAE <30m microg/mg. CONCLUSION: Elevated UAE was associated with an increased risk of CVD and all-cause mortality in all age groups from 68 to 102 years. Combining elevated UAE with the Framingham risk scores may improve risk stratification for CVD in the elderly.
Authors: Obaidullah Aseem; Brian T Smith; Marion A Cooley; Brent A Wilkerson; Kelley M Argraves; Alan T Remaley; W Scott Argraves Journal: J Am Soc Nephrol Date: 2013-12-19 Impact factor: 10.121
Authors: Kenneth J Mukamal; David S Siscovick; Ian H de Boer; Joachim H Ix; Jorge R Kizer; Luc Djoussé; Annette L Fitzpatrick; Russell P Tracy; Edward J Boyko; Steven E Kahn; Alice M Arnold Journal: J Am Geriatr Soc Date: 2018-02 Impact factor: 5.562
Authors: Paula Moreira da Costa; Arthur Fernandes Cortez; Fabio de Souza; Gabriel de Souza Mares; Bruno Dussoni Moreira Dos Santos; Elizabeth Silaid Muxfeldt Journal: J Hum Hypertens Date: 2017-12-11 Impact factor: 3.012
Authors: Jesse C Seegmiller; David R Barnidge; Bradley E Burns; Timothy S Larson; John C Lieske; Rajiv Kumar Journal: Clin Chem Date: 2009-03-26 Impact factor: 8.327
Authors: Kenneth J Mukamal; Joseph Tremaglio; David J Friedman; Joachim H Ix; Lewis H Kuller; Russell P Tracy; Martin R Pollak Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-03 Impact factor: 8.311
Authors: Michelle C Odden; Michael G Shlipak; Heather E Whitson; Ronit Katz; Patricia M Kearney; Chris defilippi; Shani Shastri; Mark J Sarnak; David S Siscovick; Mary Cushman; Bruce M Psaty; Anne B Newman Journal: Atherosclerosis Date: 2014-09-30 Impact factor: 5.162
Authors: Konstantinos Tziomalos; Emmanuel S Ganotakis; Irene F Gazi; Devaki R Nair; Dimitri P Mikhailidis Journal: Open Cardiovasc Med J Date: 2009-06-16